Tag: Drug Prices

Editorial: California needs prescription drug transparency | The Mercury News

Editorial: California needs prescription drug transparency | The Mercury News

Drug makers argue that the bill is a first step toward price controls that will decimate their research and development work. Pharmaceutical companies certainly deserve a reasonable return on their substantial investments in research and development. But if they reveal a pricing strategy that seems justified, it could have the opposite effect, relieving the pressure […]

Truveris Secures $25 Million in New Funding to Help Reduce Cost and Improve Access to Prescription Medications | Digital Journal

Truveris Secures $25 Million in New Funding to Help Reduce Cost and Improve Access to Prescription Medications | Digital Journal

“Truveris’ data-driven platform enables employers to create a more symmetrical buying process for prescription drug coverage by demystifying pricing strategies in PBM contracts and driving more transparent competition,” said Tom Rodgers, SVP & Managing Director at McKesson Ventures. “It also helps Biopharma make smarter decisions about where and how it subsidizes patient assistance programs. The […]

Bull of the Day: Jazz Pharmaceuticals (JAZZ) | Nasdaq.com

Bull of the Day: Jazz Pharmaceuticals (JAZZ) | Nasdaq.com

Following this important FDA approval, several Wall Street investment banks updated their thesis on JAZZ. Janney Montgomery Scott analyst Ken Trbovich raised his price target on $192 from $180 while maintaining a Buy rating. Trbovich believes the company can benefit from Vyxeos technology by internally developing an oncology pipeline for which the company is not […]

Congressmen Say Pricing for Multiple Sclerosis Drugs Doesn’t Add Up | Bloomberg BNA

Congressmen Say Pricing for Multiple Sclerosis Drugs Doesn’t Add Up | Bloomberg BNA

Manufacturers of multiple sclerosis drugs may be raising prices for the costly treatments in lockstep with each other, two Congressional Democrats said. Rep. Elijah E. Cummings (D-Md.), ranking member of the House Committee on Oversight and Government Reform, and Rep. Peter Welch, (D-Vt.), a senior Democrat on both the Oversight Committee and the Committee on […]

How is the draft pharma policy revamping drug price regulation? | Business Standard News

How is the draft pharma policy revamping drug price regulation? | Business Standard News

The draft pharmaceutical policy has been recently circulated by the Department of Pharmaceuticals (DOP) to a select group of organisations. Its concerns are spread across at least three ministries – DOP, health and commerce, the last for issues related to patents. The Wire earlier reported on the range of issues it aims to cover including […]

Healthcare spending, price growth slows in 2017 but job growth spikes | Healthcare Finance News

Healthcare spending, price growth slows in 2017 but job growth spikes | Healthcare Finance News

Healthcare spending growth slowed in 2016, and the trend appears to be continuing, according to the August 2017 Altarum Institute Center Health Sector Trend report. According to the report, spending grew by only 4.6 percent in 2016 and estimates based on new data have the downward trend continuing with growth for the first half of […]

When given the chance to pay less, patients choose cheaper prescription drugs | Berkeley News

When given the chance to pay less, patients choose cheaper prescription drugs | Berkeley News

As prescription drug spending continues to rise in the United States, along with prices for new and well-established drugs, insurers, employers and patients are searching for ways to cut costs. A new study led by UC Berkeley researchers found that a policy called reference pricing is effective at encouraging patients to spend significantly less on […]

Biogen & 6 Other Multiple Sclerosis Drug Stocks in Focus: Here’s Why | Nasdaq.com

Biogen & 6 Other Multiple Sclerosis Drug Stocks in Focus: Here’s Why | Nasdaq.com

Drug pricing is back in the news with an investigation being launched by Rep. Elijah E. Cummings and Rep. Peter Welch into the skyrocketing prices of multiple sclerosis (“MS”) drugs. MS, an unpredictable and often disabling disease of the central nervous system (“CNS”), interrupts the flow of information within the brain and between the brain […]

Why Pharma May Not Fear the Latest Drug-Price Probe | Bloomberg Gadfly

Why Pharma May Not Fear the Latest Drug-Price Probe | Bloomberg Gadfly

The investigation will throw an unwelcome spotlight on these companies’ pricing practices and force the release of a lot of documents they’d rather not make public. But this is a pageant we’ve seen before. As uncomfortable as it will be for the drugmakers, it may not result in much lasting damage. Behind the investigation? The fact that list prices […]

Draft pharma policy seeks to bridle NPPA’s pricing powers | domain-b.com

Draft pharma policy seeks to bridle NPPA’s pricing powers | domain-b.com

The draft pharma policy prepared by the government proposes the setting up of an advisory body to assist the National Pharmaceutical Pricing Authority (NPPA) in fixing prices, a move that would take away the drug pricing authority’s powers to fix prices. The draft pharmaceutical policy, prepared by the department of pharmaceuticals under the ministry of […]